Submit an Abstract for 2025 CCR-West (Huntington Beach, CA)

Submit your abstract to be considered for presentation at the 2025 CCR-West. Members of our faculty have agreed to lead CME-approved poster rounding in the afternoon on Friday, September 19th, 2025.

The poster presentation allows you to describe your exciting findings and interact with other experts in the field. Accepted abstracts will be printed in an abstract program book, and will also be available in the meeting app and online. Plus, with members of the press onsite, your research could have global impact! Abstracts and other meeting activities from previous CCR events have been covered in numerous media sources, creating memorable impressions.

General Information

Anyone who registers to attend the 2025 CCR-West is eligible to submit up to two abstracts. Accepted abstracts will be given as 3-minute poster presentations to poster rounding groups. Residents and fellows are also eligible to participate in the NYRIF (North American Young Rheumatology Investigators Forum) symposium the day prior to CCR, and have a separate submission portal (please visit www.nyrif.com). In addition, interesting case studies may be submitted to be considered for 10-minute oral presentations as part of the Thieves’ Market on Thursday, September 18th.

Requirements for Submissions

1. The work must describe clinical or basic research related to rheumatology; no case reports will be accepted unless submitted by a resident or fellow-in-training through NYRIF.
2. Previously published (or presented) peer-reviewed work (i.e., an “encore presentation”) is welcome.
3. All posters and presentations must be in English.
4. All presenters must be registered attendees at CCR W25.
5. Submitting authors will submit their abstract via the electronic submission portal.
6. Abstracts must meet the criteria detailed below in the Instructions for Abstract Submission section, and must be submitted before 11:59 PM on Wednesday, July 23rd, 2025.
7. Author information and a conflict of interest disclosure statement (COID) must be submitted with the abstract through the electronic portal.
8. Two investigators may not submit the same study; abstracts that appear to be two versions of a single study will be rejected. Submissions will be checked for duplication and replicate versions will be rejected.
9. Investigators will choose a category heading for their submission. Each abstract should only be submitted to one category. Please review all the abstract submission options prior to selecting and starting the submission process.
10. Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association.
11. The Program Committee endorses the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.

Policies Regarding Abstract Submission and Poster Presentations

1. There is a limit of two abstract submissions per investigator.
2. Submission of an abstract constitutes a commitment by the author to present a poster of the contents if accepted.  
3. The submitting author is considered to be the presenting author unless another coauthor is appointed to present.
4. If there will be a change in presenter, CCR staff must be notified of the change by August 15, 2025. Any such coauthor must also be registered as a CCR W25 full symposium attendee. Cancellation and a registration refund of the original author’s registration will be made according to CCR’s registration cancellation refund policies. There will be a $100 cancellation/substitution/processing fee for a change in presenter.
5. All abstracts and posters MUST contain disclosures, and a COID form must be completed and accompany the submission. If you do not have any disclosures to declare, then please put “No Disclosures” at the end of the abstract. The disclosure must also appear on the poster or attached to the poster board. You can find the COID form here, and more information about the Disclosure Policies below.
6. Failure to fully register (including COID submission) for the CCR-West meeting by August 15, 2025 will lead to the abstract being rejected.
7. The full text of the abstracts will be viewable online beginning September 15, 2025. The CCR Program Book will contain the full text of the accepted abstracts with the title, submitting author, and up to two institutions.
8. Abstracts will be printed in the CCR Program Book exactly as submitted. No editing of language use, spelling, or grammar will be performed by CCR staff.
9. After August 15, 2025, the submission system will be closed and abstracts will be sent to print. Changes may be submitted, but these will not appear in the printed materials.
10. All changes to accepted abstracts will be subject to administrative approval.
11. If you choose to withdraw an abstract after the submission deadline, this request must be received by the CCR in writing and sent to support@ccrheumatology.com prior to August 15, 2025. After this date, withdrawals will still be accepted, but abstracts may still appear in the printed syllabus.
12. Posters will be grouped by category for the poster rounding sessions.
13. The Program Committee will determine the format and order of the poster rounding.
14. Poster presentations are tentatively scheduled for Friday, September 19th, from 2:55-5:10 PM. CCR reserves the right to change the presentation time and/or date if deemed necessary.
15. Poster categories may be added, combined, or deleted at the discretion of the CCR staff.
16.  CCR does not reimburse any abstract/poster presenters for travel, hotel, or per diem expenses.
17. Minor changes may be made to the formatting to make the abstracts suitable for review on the mobile application or in the printed Program Book.

Instructions for Abstract Preparation

1. The abstract will need to be submitted via the electronic portal as a Microsoft Word document. All other documents (COID) should be submitted in PDF format.
2. Titles should reflect the contents of the abstract in ≤120 characters, not including spaces.
3. Do not italicize, underline, superscript, subscript or use all capital letters for the title.
4. Capitalize the first letter of all major words in the title.
5. Do not add a period at the end of the title.
6. Abbreviations are not allowed in the title unless they are well-known/standard abbreviations (e.g., DNA, TNF, IL-6)
7. Do not use brand/trade names for pharmaceuticals or medical devices. Please use the generic term (e.g., use “pegloticase” rather than “Krystexxa”)
8. Please list authors under the title line. Up to two affiliations may be added per author.
9. Do not list authors with initials only; please list all authors’ complete first and last names.
10. If an author's name appears on more than one abstract, their name must appear and be spelled identically on each abstract in order to facilitate proper indexing. If the presenter is not an author, then the presenter’s name should be identified as the presenter under the authors’ names at the top of the abstract.
11. Do not include titles or degrees for the authors, and do not put contact information in the abstract.
12. Abstracts should be ≤2500 characters, excluding spaces, the title, author information, references, disclosures and any graphs, tables, figures or images.
13. A maximum of 5 graphs, tables, figures, or images that enhance the understanding of the abstract may be included (but are not necessary). The table(s)/figure(s) and their legends will not be included in the character count. They must be submitted as part of the abstract, and cannot be sent later or as a separate submission.
14. All abstracts should be single-spaced, in Times New Roman 12-point font. Special characters should be inserted using the “Symbols” font in MS Word. The use of other software or fonts may lead to the abstracts being unreadable or to the insertion of incorrect symbols.
15. For general abstracts, please structure the contents into Background, Methods, Results, and Conclusion sections. The Conclusion should state the main clinical implications, significance, or relevance of your study.
16. Clarity of expression will be considered in the review process. The overall quality of the language used should assure comprehension by the reader. Please check grammar, spelling and punctuation to ensure that your text is readable and representative of your work.
17. Avoid the use of abbreviations whenever possible. Place define all abbreviations the first time they appear in the text, first writing out the full term and noting the abbreviation in parentheses after it.
18. Use a comma for numbers 1,000 and above.
19. Revisions to your submission can be made until August 15, 2025. Please be certain to notify CCR staff if you have made or uploaded a revision so that the newest version will be used. Any changes made after August 15, 2025 will not appear in the printed version of the abstract, and may not appear online or in the app. This includes adding or removing authors or changing presenters.

How to Submit Abstracts via the Online Portal

All abstracts must be submitted electronically via the online submission system.

1. Log in to your existing account, or create a new user account and fill in your contact details.
2. If you are a trainee (resident, fellow, or medical student), please register through the separate NYRIF portal.
3. On the main page, click the “Abstract Submission” button and complete the forms.
4. You will automatically be entered as the Presenting Author. You will be the only person to receive correspondence from CCR regarding your abstract.
5. Upload your abstract as a Microsoft Word document (.docx format).
6. Fill out and electronically sign the COID form, which can be found here.
7. Ensure that you have filled in all blanks, selected options for all drop-down boxes, and filled all checkmarks. If there are incorrect or missing data, your abstract will remain a draft (errors detected), and will not be submitted.
8. You will receive an email confirming your submission. If you do not receive an email within 24 hours of submitting your abstract, be sure to check your junk mail/spam folder. If you still cannot fine an email confirming the submission, contact support@ccrheumatology.com.
9. You may also check the Edit Abstract page in your user account. If the entry is marked “draft”, open it and look at the sections listed on the left. Completed sections will have a check mark. Incomplete or incorrectly submitted sections will have an ‘x’. The “Review” page will list any errors in the submission. Once all are fixed, you will be able to click the “Submit” box.
10. If you would like to submit a second abstract, repeat the steps above with the new submission.
11. Monitor your email regarding the acceptance of your abstract for a poster presentation. If you do not receive an email regarding acceptance within 7 days of submission, and have checked your spam/junk email folder, contact support@ccrheumatology.com.

Disclosure Policies and Poster Presentation

1. The presenter and lead investigator MUST have their disclosure information on all abstracts and posters. A completed and signed COID form MUST be submitted with the abstract.
2. Presenting authors and lead investigators will be asked to comply with the ACCME Disclosure Policy. Indication of the relationship and any associated commercial entity is required for all presenting authors and the lead investigators.
3. The presenting author may be an employee of a pharmaceutical company as long as the presenter's Conflict of Interest in the written abstract, on the poster, and the COID form accurately states any and all relationship(s) of the presenter to the company.
4. Presenters must include a disclosure statement in the abstract and on the poster, and must also verbally disclose any pertinent conflicts of interest at the beginning of their presentations. Any non-author presenters must have integral information about the integrity of the data and accuracy of the data analysis, and can attest that the data were approved for presentation. The disclosure for posters being presented by non-authors must still contain the main conflicts of interest that the authors would have disclosed.
5. All disclosures from presenting authors and lead investigators must be received by July 16, 2025 in order for an abstract to be considered.
6. Failure of the lead investigator or other approved presenter to submit a completed COID form and disclosure information on an abstract or poster will result in the removal of an accepted abstract and poster from the program.
7. Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers and/or research sponsors (including, but not limited to, academic institutions, commercial entities, and non‐profit organizations).
8. Only one presenter is permitted per abstract.
9. Important: The presenting author is the sole point of contact for all abstract co-authors. CCR will direct all co-author inquiries to the submitter.

Poster Preparation

1. Poster presentations and faculty rounding by thought leaders will be in the afternoon on Friday, September 19, 2025. The posters should be up by Noon on Thursday, September 18, 2025 and remain up until the conclusion of the poster rounding session Friday night for attendee viewing. No poster should be removed prior to 6PM on Friday September 19th, or the responsible party may forfeit any future poster submissions. Once the faculty rounding session has concluded, posters should be removed. Any posters remaining on poster boards or on the floor of the poster area will be removed and discarded if not removed by the presenter.
2.  Presenters are required to attend their boards during the 2:55-5:10 PM faculty poster rounding session on Friday.
3. Poster boards will be grouped together based on subject matter. Presenters with two posters in different categories may not have their posters grouped together. The location of the posters within the Poster Session areas is at the discretion of CCR staff.
4. Presenters must post disclosures somewhere on their poster board. Failure to follow these guidelines will result in your poster being removed and may jeopardize your presentations at future meetings.
5. Each poster display board measures four feet high (121 cm) and eight feet wide (244 cm), but this includes the frame for the board. We recommend that the dimensions of your poster not exceed 3 ft 6 inches by 7 feet. Push pins will be provided to hang your poster. There will be one poster board per abstract.
6. Text should be readable from at least three feet away.
7. No audiovisual, projection, or computer equipment requiring electrical power will be permitted in the general poster session area.
8. The presenter is responsible for printing and bringing their poster(s). CCR does not print posters or pay for poster printing.

Permission and Reprints

It should be noted that all abstracts and posters will appear online and be printed and distributed at the CCR-W25 meeting. Poster rounding sessions will also be recorded and available for viewing online by registrants. Please ensure that all necessary permissions for publication have been obtained prior to submission of the abstract. The CCR-West 2025 Annual Meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by CCR. The information and materials displayed and presented during this meeting are the property of the CCR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without the written permission of the Congress of Clinical Rheumatology and the presenter. Any use of the program content for commercial purposes (which includes, but is not limited to, oral presentations, audiovisual materials used by speakers, and program handouts) without the written consent of the CCR is prohibited. This policy applies before, during, and after the meeting. The CCR will enforce its intellectual property rights and penalize those who infringe upon them.